About: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 1999 (uk) im Dezember 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 1999 (ast) scientific article published on 01 December 1999 (en)
publication date	wds:Q73231145-EFA6E5BB-69D3-4F8A-9DC3-123D1B628039
publication date	1999-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73231145-7B41161D-4D79-4451-9E0D-5506A1FC84D3
language of work or name	English
cites work	wds:Q73231145-33282654-A25A-4233-805C-838E22382EC4 wds:Q73231145-3FCA8AAA-9CED-4C70-AB55-36B070C88C45 wds:Q73231145-5FA21E89-E9CB-4208-A5BB-E67B5EEA8ECE wds:Q73231145-69350AC4-1AD0-4CF9-86FB-5984FDCC82F2 wds:Q73231145-D970820C-196B-4F34-BAE3-C4D8EF4F85E8 wds:Q73231145-E9EC5AC6-9CA3-48D4-97F1-1A6684381232 wds:Q73231145-EF1DA274-B6EB-4D34-862B-0B9C4B39B131 wds:Q73231145-FACA3DCD-FD44-49AF-A846-8D683DFEF19B
cites work	Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Fluorodeoxyuridine synchronization of bone marrow cultures Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood
author name string	wds:Q73231145-3D82D731-B8C7-43EF-A2F1-D31561E86DE4 wds:Q73231145-4BEC83A0-ABB5-42EA-AF82-6B9E5A7DA927
author name string	Z Rudzki S Branford
rdfs:label	Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (en) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (nl)
skos:prefLabel	Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (en) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (nl)
name	Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (en) Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (nl)
author	wds:Q73231145-8D9CABBE-AFAF-4203-9BCA-E761912D4798
author	Timothy Hughes
title	wds:Q73231145-4F22F135-FF55-4654-9354-7D5142FC35F3
title	Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics (en)
page(s)	wds:Q73231145-3EBFDD5C-8B14-4C64-8BE3-9CE1ADFA94DD
page(s)	587-599
instance of	wds:Q73231145-22EBB8EA-BD5C-40BD-86A9-F73EBF20830F
instance of	scholarly article
main subject	wds:Q73231145-2F33238E-89D6-46CE-AAAB-7111E65CE543
main subject	cytogenetics
PubMed ID	wds:Q73231145-AD47B785-BB8A-4329-AFDF-DEAE8C381925
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10583264
PubMed ID	10583264
published in	wds:Q73231145-0F75D573-43C4-4942-B95C-A57ECF71415E
published in	British Journal of Haematology
issue	wds:Q73231145-2E9890A7-E650-4A7E-868B-11BA579D9F9D
volume	wds:Q73231145-FF18097B-995E-4374-844F-CCE88DEADF3D
issue	3
volume	107
DOI	wds:Q73231145-617F92E9-CA29-4F34-8124-C2F107B2CD47
DOI	http://dx.doi.org/10.1046/J.1365-2141.1999.01749.X
DOI	10.1046/J.1365-2141.1999.01749.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73231145
is cites work of	Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. Dynamics of chronic myeloid leukaemia. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate The molecular biology of cancer Role of stem cells in cancer therapy and cancer stem cells: a review PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Detection of minimal residual disease Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes An approach to the management of chronic myeloid leukemia in British Columbia Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Frequent upregulation of MYC in plasma cell leukemia. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues Current practices in the management of chronic myeloid leukemia. Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays? Chronic myelogenous leukemia: laboratory diagnosis and monitoring Stem cells and cancer: an overview Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients Monitoring molecular response in chronic myeloid leukemia Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Resistance to imatinib (Glivec): update on clinical mechanisms Real-time PCR quantitation of glucocorticoid receptor alpha isoform A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system Establishment and study of different real-time polymerase chain reaction assays for the quantification of cells with deletions of chromosome 7. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software